ISMP Medication Safety Alert! Action Agenda 2nd Quarter 2022
ISMP faculty reviews priority findings and recommendations from the recent ISMP Medication Safety Alert! Acute Care edition newsletter Action Agendas. ISMP faculty will describe the cause of often-preventable medication safety issues including but not limited to Covid-19 vaccine mix ups, errors with hypertonic saline, monoclonal antibodies errors, and glycemic events. Faculty will discuss meaningful recommendations for early detection as proven prevention strategies.
Participants in this program will learn how they can use this timely information to immediately address issues in their organization in support a robust medication safety program.
Target Audience
Physicians
Nurses
Pharmacists
Pharmacy Techs
Learning Objectives
At the conclusion of this activity, participants should be able to:
1. Recall three error/hazard examples that have been reported to the ISMP Medication Safety Error Reporting Program (ISMP MERP) during the second quarter of 2022.
2. Describe how external medication safety information can be used regularly to support improved as part of a robust medication safety program.
3. Discuss strategies to prevent harm with the use of neuromuscular blocking agents.
Pharmacists learning objectives
At the conclusion of this activity, pharmacists should be able to:
1. Recall three error/hazard examples that have been reported to the ISMP Medication Safety Error Reporting Program (ISMP MERP) during the second quarter of 2022.
2. Describe how external medication safety information can be used regularly to support improved as part of a robust medication safety program.
3. Discuss strategies to prevent harm with the use of neuromuscular blocking agents.
Pharmacy technician learning objectives
At the conclusion of this activity, pharmacy technicians should be able to:
1. Recall three error/hazard examples that have been reported to the ISMP Medication Safety Error Reporting Program (ISMP MERP) during the second quarter of 2022.
2. Describe how external medication safety information can be used regularly to support improved as part of a robust medication safety program.
Additional Information
Attachment | Size |
---|---|
Helpful Tips for Users - Vizient CE System.pdf | 134.81 KB |
CE Information for Credit - Live_2022.docx | 123.35 KB |
Faculty
Michael R. Cohen, RPh, MS, ScD (hon.), DPS (hon.), FASHP
President Emeritus ISMP
ISMP
Planning committee
Jackie Stokes, BS
Manager, Pharmacy Program
Vizient
Gretchen Brummel, PharmD, BCPS
Consulting Solutions Director
Vizient
Ellen Flynn, RN, MBA, JD
AVP, Programs
Vizient
Tomas Villanueva, DO, MBA, FACPE, SFHM
Senior Principal
Clinical Operations and Quality
Vizient
Matthew Grissinger, RPh, FISMP, FASCP
Director, Education
ISMP
Identification, Mitigation, and Disclosure of Relevant Financial Relationships
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
Disclosure of Financial Relationships:
Absence of Relevant Financial Relationships
Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
No one in a position to control the content of this educational activity have relevant financial relationships with ineligible companies.
Statement of content validity
Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Designation Statement(s):
NURSING
This activity is designated for 1.00 contact hours.
PHARMACY
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
- UAN JA0006103-0000-22-049-L05-P
- UAN JA0006103-0000-22-049-L05-T
PHYSICIAN
Vizient, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC